Investors of Nektar Therapeutics Stock May Have Legal Claims – NKTR

Investors of Nektar Therapeutics Stock Since At Least June 2022 Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Nektar Therapeutics (“Nektar” or “Nektar Therapeutics”) (NASDAQ: NKTR) breached their fiduciary duties to Nektar and its shareholders.

The investigation concerns whether members of Nektar’s board of directors or senior management failed to manage Nektar Therapeutics in an acceptable manner, in breach of their fiduciary duties to Nektar, and whether Nektar Therapeutics and its shareholders have suffered damages as a result.

INVESTORS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR NKTR STOCK SINCE AT LEAST JUNE 2022 ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR NKTR SECURITIES.
SHAREHOLDERS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR STOCK SINCE AT LEAST JUNE 2022 ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Investors of Nektar Therapeutics May Have Legal Claims - NASDAQ: NKTR

Securities Investigation – Fulcrum Therapeutics Stock – FULC

Investors of Fulcrum Therapeutics Stock Encouraged to Contact Kehoe Law Firm, P.C. 
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fulcrum Therapeutics, Inc. (“Fulcrum” or “Fulcrum Therapeutics”) (NASDAQ: FULC).

On February 24, 2023, shares of Fulcrum Therapeutics stock closed down more than 56%, after Fulcrum ” . . . announced that on February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease. The [FDA] indicated that it would provide a formal Clinical Hold Letter to the company within 30 days.”

Fulcrum Therapeutics also reported that “[t]he clinical hold was initiated by the [FDA] due to previously reported preclinical data. Fulcrum will suspend dosing in the Phase 1b trial of FTX-6058 and intends to work diligently with the [FDA] to resolve the hold as soon as possible.”

INVESTORS OF FULCRUM THERAPEUTICS STOCK WHO HAVE SUFFERED LOSSES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR SECURITIES.
SHAREHOLDERS OF FULCRUM ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Investors of Fulcrum Therapeutics Stock May Have Legal Claims - NASDAQ: FULC

Kehoe Law Firm on Behalf of and its Client Southeastern Pennsylvania Transportation Authority Pension Plan (“SEPTA”) and International Brotherhood of Teamsters Local 710 Move to Intervene in Abbott Inc. Shareholder Derivative Action

Southeastern Pennsylvania Transportation Authority Pension Plan and Teamsters Local 710 have moved to intervene in the Abbott Inc. Derivative Litigation pending in the Northern District of Illinois. The lawsuit, filed in October 2022, alleges wrongdoing by certain officers and directors of Abbott at least during the period from November 19, 2021, through June 8, 2022.

Specifically, the Individual Defendants are alleged to have breached their fiduciary duties and to have violated federal securities laws by concealing lapses in safety protocols at Abbott’s Sturgis, Michigan facility. These lapses resulted in environmental contamination with Cronobacter sakazakii bacteria, a critical issue affecting the manufacturing of infant formula.

In February 2022, the FDA reportedly confirmed Cronobacter contamination at the Sturgis facility, leading to a recall of various infant formula products. According to the complaint, Abbott executives portrayed the recall as a proactive measure to protect the public, not disclosing the FDA investigation.

Abbott eventually closed the Sturgis facility due to safety concerns, causing massive formula shortages in the U.S., Canada, and other markets. The federal government invoked the Defense Production Act to address the shortages. 

In May 2022, the Senate Finance Committee launched an investigation into Abbott’s international tax practices and stock buybacks, linking them to the Sturgis facility issues.  Not until June 2022 did Abbott disclose that it was aware of the whistleblower complaint in early 2021, contributing to a decline in the company’s stock price.

The actions during the Relevant Period led to significant repercussions, including stock decline, a class action lawsuit, and potential liability exposure for Abbott.

SEPTA and Teamsters Local 710 have moved to intervene in this derivative action, captioned In Re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, 1:22-CV-5513 (N.D. IL), thereby demonstrating their commitment to protecting shareholder interests and holding Abbott’s officers and directors accountable for alleged misconduct.

John A. Kehoe, Partner at Kehoe Law Firm, commented: “We are pleased to see Southeastern Pennsylvania Transportation Authority Pension Plan and Teamsters Local 710 take a stand in intervening in the Abbott shareholder derivative action. Institutional shareholders play a crucial role in holding corporations accountable for their actions and advocating for positive governance reforms. This intervention marks a step towards transparency, accountability, and responsible corporate practices.” 

For more information about Kehoe Law Firm and its involvement in this matter, please contact John A. Kehoe at [email protected] or call (215) 792-6676.